Revenue beat masked by soft domestic organic and maintained cautious guidance

Delivered ₹2,580.4 Cr, 22.8% YoY confirmed; but domestic organic (ex-in-licensed) only 6–7%, intl inflated by ARV surge (~2/3 of RoW) and ~6–7% forex tailwind

EBITDA ₹508 Cr at 19.7% margin confirmed; but achieved despite gross margin falling to 58.4% from 60%+ (mix shift: intl ARV/Ampho, lower-margin B2B). Expansion via SG&A control, not operational excellence.

Organic domestic (ex-Sanofi OAD, Roche, Poviztra) was 6–7%, not 10.2%. Zaventus attrition stopped but still weak; management expects acceleration Q2H via low base effect, not organic momentum.

ARV is ~2/3 of RoW in Q1; management guided ARV to normalize to 50–55% of RoW for full year, implying base non-ARV is much weaker. 44.8% overstates sustainable growth.

Management admitted market is noisy (40–50 brands launched), channel stocking vs. actual consumption unclear, jury still out on traction. Framed as month-on-month growth but qualified with significant caveats; not bullish despite confident framing.

Q1 delivered 22.8%, well above low-to-mid-teen (11–14%) guidance, yet management re-affirmed the same range. Suggests either conservative positioning or expectation of moderation in coming quarters.

Q1 10.2% headline domestic growth, but 6–7% organic ex-in-licensed products (Sanofi OAD, Roche). This is below company historical 12%+ and below implied FY27 low-to-mid-teen guidance. Zuventus stabilization is ongoing, not complete.

Gross margin 58.4% vs. 60%+ prior; management guided to 59% FY27 due to intl mix (Europe, ARV). EBITDA margin still expanding via cost discipline, but quality of growth degraded.

Management candid on market noise (40–50 brands), channel stocking risk, and competitive intensity. Approval for MASH is a catalyst, but traction remains unproven. Month-on-month growth claimed but not quantified.

Q1 ARV ~2/3 of RoW (44.8% growth); management guided ARV to 50–55% of RoW for full year, implying non-ARV growth is single-digit or flat. Q1 44.8% overstates sustainable momentum.

Management maintained 'low to mid-teen FY27 revenue growth' and '70–100 bps EBITDA margin expansion' despite Q1 delivering 22.8% growth. This suggests either conservative positioning or expectation of moderation; forward visibility cautious.

Organic ~6–7% ex-in-licensed. From Q2 onwards, OAD in base. Expected to reach par with industry Q2, then faster in 2H due to Zuventus acceleration and low base effect.

ARV ~2/3 of Q1 RoW. For full year, expect ARV to normalize to 50–55% of RoW business. Non-ARV growth also happening, so base business solid for FY28.

FY27 expected ~59% due to international business (Europe, ARV) outperforming. Guided to 60–61% at start of year, but raising intl guidance pushes gross margin down. EBITDA accretion more important than gross margin in these markets.

Month-on-month traction. MASH approval 15 days ago opens hepatology/GI. But 40–50 brands launched, jury out on channel stocking vs. actual consumption 3–6 months. We're competitive on pricing, rDNA molecule, innovator association. Survival of fittest; confidence in long-term position.

Product in all countries; tender-based procurement with cycles. Should pick up next quarter as supplies ramp. Order book to grow in line with supplies.

Filing in next few months. Global development tagged with domestic. Delay in expansion discussions; most markets with patent expiry now second-wave filings (vs. March expiry). Decent product but not a major growth driver; one of portfolio.

Defer to Reddy's. Whenever we get supplies, we'll launch. Depends on Reddy's supply shape-up.

Three phases: stability, consolidation, acceleration. Achieved stability (attrition stopped), consolidation nearly done. Now moving to acceleration. Most of the job done; expect good traction Q2H. No longer a worry; question of high growth now.

4–5% of revenue for full year. Q1 lower; expected to pick up rest of year.

By end FY28. Q2 will see ~₹450–500 Cr debt increase from M&A payouts. Net debt now ₹1,103 Cr; by Q2 end ~₹1,450 Cr. Working capital normalized in July; will come back in Q2.

Reaffirmed by management despite Q1 beat of 22.8%. Suggests caution on forward quarters or expectation of moderation. Dependent on Zuventus acceleration (Q2H), intl momentum (ARV normalization), and Poviztra/semaglutide adoption.

50 bps delivered in Q1. Path to 70–100 bps requires continued cost control; gross margin expected to stay under 60% due to international mix shift, but EBITDA accretion via B2B models more important.

Downgrade from prior due to Europe and ARV (lower-margin B2B) outperforming. International at 12–13% constant currency, domestic mix intact; full-year 59% expected.

Q1 R&D ₹90 Cr (3.5%); expected to ramp rest of year. Supports pipeline delivery (15+ approvals Q1, Ampho, biosimilars) but upside risk if capex required for manufacturing expansion.

Organic domestic (ex-in-licensed) at 6–7% vs. company 12%+ historical and FY27 low-to-mid-teen target. Zaventus acceleration dependent on low base from prior-year consolidation challenges. If consolidation extends or competitive pressure rises, domestic miss FY27 guidance.

RoW 44.8% growth heavily skewed by ARV (~2/3 of business). Management guided ARV to normalize to 50–55% of RoW for full year, implying base non-ARV growth is flat to low single-digit. If ARV pricing pressure accelerates or competitor launches undercut market, growth deceleration sharp. Forex also a tailwind masking constant-currency weakness.

Poviztra (Novo Nordisk semaglutide partnership) positioned as growth catalyst in obesity market, but management explicitly cautioned: 40–50 brands launched, channel stocking vs. actual consumption unclear, 'jury is out' 3–6 months. MASH indication approval is positive, but market adoption remains unproven. If adoption slower than guided or channel inventory builds without consumption, domestic growth miss.

Gross margin 58.4% vs. 60%+ prior, driven by international (Europe, ARV, B2B models) growing faster than domestic. Management expects FY27 gross margin ~59% vs. start-of-year guidance 60–61%. While EBITDA margin expanding (+50 bps via cost control), the trend suggests growth is in lower-quality businesses. If international outperformance continues, gross margin may stay under 59%, capping EBITDA expansion.

Semaglutide for Quebec planned Q2 entry, now pushed to potential November (via Reddy's relaunch). Emcure dependent on Reddy's supply to launch. Delayed entry means competitive advantage erosion; second-wave entry (vs. March patent expiry) already implies late positioning. If supply further delays, Emcure loses momentum in high-growth obesity market.

International growth benefited from ~6–7% forex tailwind (intl constant-currency growth 12–13%, reported 34.2%). If rupee appreciates, reported growth will fall sharply even if underlying business stable. Q1's beat was partially currency-aided; if macro weakens rupee further or RBI tightens, forex benefit may reverse.